Next-Generation Cardiac Care - join this SimCardioTest event

The upcoming events promise an immersive experience, unveiling the cutting-edge in-silico platform developed within the SimCardioTest project. Participants will discover the platform's advanced features created to help industry in the medical product development.

We are thrilled to present not only the scientific underpinnings but also the user experience of our innovative platform.

Furthermore, we are eager to engage with clinicians and industry stakeholders, collecting valuable feedback that will provide us with crucial insights.

This interactive session aims to foster a deeper understanding of the three new products integrated into the platform, allowing us to refine and optimize their functionalities based on the real-world perspectives of industry experts. The workshop promises to be a collaborative and enlightening experience, marking a significant step forward in the evolution of our in-silico trials solution.

Embrace the SimCardioTest in-silico trials platform, discover why

Medical device companies:

• reduce time and costs for the development of medical devices (LAAO, pacing leads)
• establish collaborations to enrich platform’s features and assess a new medical device design across populations
• Get safer medical devices into the hands of patients faster.
• reduce, refine, and partially replace (pre-)clinical testing

Pharma companies:

• assess the cardiac toxicity of your drugs
• establish collaborations to enrich platform’s features and assess new drugs across populations
• safer drugs reach patients faster
• reduce, refine, and partially replace (pre-)clinical testing

Clinicians/cardiologists

• ascertain the most suitable treatment for your patients
• identify the risks of cardiotoxic consequences for a specific patient
• find the appropriate medical device design for your patients
• start collaboration to enrich platform’s features and assess new drugs across populations

SIMCARDIOTEST FOR CARDIAC DISEASE

SimCardioTest is a project being funded by the European Commission to develop a standardized and secure cloud-based platform where in silico trials run seamlessly.

The novel platform presents an in-silico testing environment validated and positioned beyond the state-of-the-art in computational tissue models developed by the academic partners participating in the project.

The cloud-based platform integrates computational models for three different applications:

1. Cardiac pacing devices
2. Left atrial appendage occluders
3. Electrophysiological & electromechanical safety and efficacy of drugs

Simulations can be setup and run on the cloud by setting input parameters and viewing the results on the platform interfaces.

SimCardioTest is challenging today’s huge burden of cardiovascular diseases on the population worldwide with in-silico testing. It has the potential to transform the existing paradigm of pre-market clinical trials, while reducing their costs and accelerating the availability of medical drugs/devices. Among other benefits, this testing platform shall demonstrate the possibility to perform experiments in controlled conditions and cohorts, repeat experiments as often as needed and test therapies for patient-specific pathologies.

The cardiac in silico platform: a platform for testing new product designs

The platform will allow to verify and validate new designs of pacing leads/devices as well as new designs of left Atrial Appendage Occluders (LAAO) and their interaction with the heart in terms of efficacy and safety. The computational models have been thoroughly verified and validated, and are therefore trustworthy.

The cardiac in silico platform: a platform for testing new product designs: a Cloud-based platform as a vector to promote disruptive technology

The platform will offer an interface for health researchers and professionals to run simulations. This will be an opportunity to discover an innovative approach to personalised pharmaco-kinetics meta-modelling, and potentially use it for other diseases

Host or Publisher Michele Barbier et Maxime Sermesant